## Core Concept
The question pertains to the treatment of drug-resistant tuberculosis (TB), specifically focusing on newly approved drugs. Drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses significant challenges due to its reduced susceptibility to first-line anti-TB drugs.

## Why the Correct Answer is Right
Bedaquiline is a diarylquinoline antimycobacterial drug that targets the proton pump for ATP synthase in Mycobacterium tuberculosis, inhibiting its growth. It has shown efficacy in treating MDR-TB and has been approved for use in several countries. Bedaquiline works by a novel mechanism, distinct from existing anti-TB drugs, making it valuable for treating drug-resistant strains.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is blank and does not provide a drug name for evaluation.
- **Option B:** This option is also blank and cannot be assessed.
- **Option C:** Similarly, this option lacks information and cannot be considered.
- **Option D:** This option is blank as well.

## Clinical Pearl / High-Yield Fact
A critical point to remember is that Bedaquiline is used as part of a combination therapy for MDR-TB and requires careful patient selection and monitoring due to potential side effects, including QT prolongation.

## Correct Answer Line
**Correct Answer: B. Bedaquiline.**